Sign in

Ben Rossi

Research Analyst at JPMorgan Chase & Co.

Ben Rossi is an Executive Director and equity research analyst at JPMorgan Chase & Co., focused on the healthcare and medical supplies sector with a particular emphasis on medical care facilities. He covers publicly traded companies including HCA Healthcare, Universal Health Services, Tenet Healthcare, and Ardent Health Partners, and has achieved a 60% success rate with an average return of 14.77% on analyst calls. Rossi began his career at BMO Capital Markets before joining JPMorgan in 2024, where he has built a track record for thorough sector coverage and insight. He holds relevant industry credentials and actively participates in investor communications and healthcare policy discussions.

Ben Rossi's questions to HCA Healthcare (HCA) leadership

Question · Q3 2025

Ben Rossi asked about HCA's capacity for incremental volumes in Q4, the incremental cost to manage additional throughput, and any variance across markets in ramping up capacity cost-effectively.

Answer

CEO Sam Hazen stated no significant capacity constraints, citing improved net headcount and programmatic efforts to meet demand. He highlighted specific surge planning and increased physical capacity coming online in 2026. CFO Mike Marks added that length of stay management efforts also help create room for volume growth.

Ask follow-up questions

Question · Q3 2025

Ben Rossi with JPMorgan Chase & Co. inquired about HCA's capacity for incremental volumes, the incremental cost to manage additional throughput, and any market variances in ramping up capacity cost-effectively.

Answer

CEO Sam Hazen stated no significant capacity constraints, citing improved net headcount and programmatic efforts to meet demand. He highlighted increased capital coming online in 2026, adding physical capacity. CFO Mike Marks added that length of stay management efforts also create additional room for volume growth.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts